Abstract Ability of the heart to undergo pathological or physiological hypertrophy upon increased wall stress is critical for long-term compensatory function in response to increased workload demand. While substantial information has been published on the nature of the fundamental molecular signaling involved in hypertrophy, the role of extracellular matrix protein Fibronectin (Fn) in hypertrophic signaling is unclear. The objective of the study was to delineate the role of Fn during pressure overload-induced pathological cardiac hypertrophy and physiological growth prompted by exercise. Genetic conditional ablation of Fn in adulthood blunts cardiomyocyte hypertrophy upon pressure overload via attenuated activation of nuclear factor of activated T cells (NFAT). Loss of Fn delays development of heart failure and improves survival. In contrast, genetic deletion of Fn has no impact on physiological cardiac growth induced by voluntary wheel running. Down-regulation of the transcription factor c/EBPb (Ccaat-enhanced binding protein b), which is essential for induction of the physiological growth program, is unaffected by Fn deletion. Nuclear NFAT translocation is triggered by Fn in conjunction with up-regulation of the fetal gene program and hypertrophy of cardiomyocytes in vitro. Furthermore, activation of the physiological gene program induced by insulin stimulation in vitro is attenuated by Fn, whereas insulin had no impact on Fn-induced pathological growth program. Fn contributes to pathological cardiomyocyte hypertrophy in vitro and in vivo via NFAT activation. Fn is dispensable for physiological growth in vivo, and Fn attenuates the activation of the physiological growth program in vitro.
Introduction
Hypertrophy is the primary phenotypic characteristic of cardiomyocytes in response to increased functional demand that reduces wall stress and maintains cardiac output. Physiological hypertrophy is induced by endurance exercise, resulting in enhanced cardiac function with increased output under stress. In contrast, pathological hypertrophy due to pressure or volume overload ultimately leads to decompensated heart failure (HF) associated with reduced survival. Priming cardiac tissue with physiological hypertrophy decreases susceptibility to failure if the heart is secondarily stressed with a pathological stimulus in rodents [23] . Supervised exercise training in HF patients improves clinical presentation, hospitalization rates and most likely survival [30] . Therefore, striking a balance between physiological versus pathological hypertrophic growth programs is critical to maximize successful longterm outcome.
Pathological hypertrophic growth is characterized by induction of natriuretic peptides [atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)] and reactivation of the fetal gene program, namely a-skeletal actin and bmyosin heavy chain (aSA, bMHC). The calcineurinNuclear Factor of Activated T cell (Cn-NFAT) cascade is a major signaling pathway essential and sufficient for pathological hypertrophy, but seemingly irrelevant for physiological growth [43] . Activated Cn dephosphorylates NFAT resulting in nuclear translocation and activation of the pro-hypertrophic fetal gene program [12, 41] . Regulator of CAlcineuriN 1.4 (RCAN1.4) expression is induced due to several NFAT binding motifs in its promoter region and correlates with NFAT cascade activation [28] . In contrast, physiological growth significantly increases heart weight without reactivation of the fetal gene program or induction of natriuretic peptides [22] . Down-regulation of the transcription factor c/EBPb (Ccaat-enhanced binding protein b) plays a decisive role in physiological hypertrophy through induction of a distinct transcriptional program involving increased expression of aMHC, CITED4 (cbp/p300 interacting transactivator 4) and PGC1a (peroxisome proliferatoractivated receptor gamma coactivator 1a) [4] , although induction of PGC1a expression might be controversial in the literature [19] .
Extracellular matrix (ECM) is a pivotal component of myocardial remodeling responses during homeostasis and pathological injury, providing both structural support and essential signaling cues. Expression of the ECM protein Fibronectin (Fn) is elevated during early postnatal development and declines with progression to adulthood [8] . After pathological injury such as myocardial infarction or pressure overload, Fn expression is reinduced as a characteristic part of pathologic remodeling [14, 18] . Short-term induction of Fn following pathological injury may be tied to a beneficial role in myocardial reparative response by promoting cardiac resident stem cell proliferation [13, 16] . Determination of the role for Fn in the context of adult myocardial remodeling has proven challenging since genetic deletion of Fn results in embryonic lethality [16] . As such, involvement of Fn for physiological as well as pathological cardiomyocyte growth in the adult heart has not been determined. Published studies indicate that hypertrophy of neonatal cardiomyocytes in vitro is induced by Fn [6, 27, 39] , but no further assessment of Fn participation in hypertrophic growth of the intact heart has been described. Therefore, this study details the role of Fn in pathological growth induced by transaortic constriction (TAC) or alternatively voluntary wheel running for induction of physiological growth. An inducible genetic deletion of Fn in transgenic mice was established and tested in both models to elucidate the role of Fn on the balance of both described growth programs.
Methods

Animals
To create inducible Fn knockdown animals, mice expressing tamoxifen-sensitive Cre under CMV-enhanced global actin promoter (Cre ?/-, Jackson, #004682) were crossed for two generations with mice homozygous floxed for fibronectin (Fn fl/fl , generously provided by Prof. Dr. Reinhard Fässler) [35] . The obtained mice (Cre ?/-Fn fl/fl ) were breed with Fn fl/fl animals for multiple generations to build up the colony. Both mice strains have a C57BL/6 background. At the age of 8 weeks, all mice received Tamoxifen intra-peritoneally for 10 days 1 mg/day resuspended in a 1:10 mixture of 100 % ethanol in sunflower oil to induce recombination. Cre ?/-Fn fl/fl mice were considered knockdown animals, whereas Cre-negative littermates represent controls. The experiments were started at the age of 12 weeks. The 4-week window allowed successful knockdown of Fn since the half-life time for Fn has been reported to be between 13 h and 3.5 days [32] [29] . The 4-week voluntary running experiment has been performed as described recently [5] . The Institutional Animal Care and Use Committee of San Diego State University approved all animal procedures and treatments.
Cardiomyocyte isolation, treatment and culture Neonatal rat cardiomyocytes (NRCMs) were isolated from hearts of 1-2-day-old neonatal rats by trypsin digestion using standard procedures. After enzymatic digestion, cell preparations were preplated for 2 h in M199 medium (CellGro) with 15 % fetal bovine serum (FBS) to reduce nonmyocyte contamination. NRCMs were plated in dishes pretreated with gelatin (0.1 %, Sigma), or Fn (20 lg/mL) together with gelatin for 2 h at 37°C. For cellular hypertrophy experiments in vitro, NRCMs were cultured with low serum media (0.5 % FCS) for 48 h.
Surgical procedures and echocardiographic assessment
Twelve-week-old male animals were anesthetized under isoflurane 2 %, intubated, and ventilated. A thoracotomy was performed and the aorta has been ligated using a 7-0 suture between the innominate and left common carotid artery with an overlying 26-gauge needle. After ligation, the needle was withdrawn. Consecutive non-invasive assessment of cardiac function in the parasternal short axis view in M-mode has been performed after 1, 2, 4, 6 and 8 weeks post-surgery. Echocardiographic assessment of function as well as surgery and data analysis were performed in a blinded fashion. Echocardiography was performed under mild isoflurane sedation (0.5-1.5 %) using a Vevo 770 High resolution system. For histochemistry, hearts were arrested in diastole using high cadmium solution and perfused with phosphate-buffered formalin for 15 min (Sigma-Aldrich) via retrograde canulation of the abdominal aorta. Retroperfused hearts were removed from the chest cavity and placed in formalin for at least another 24 h. Alternatively for whole heart lysates, hearts were removed directly and frozen down in liquid nitrogen until further processing.
(Immuno-) histochemistry Heart sections were deparaffinized and rehydrated using consecutive incubations in alcohol with decreasing concentrations and finally incubated in distilled water. For antigen retrieval, specimens were boiled for 15 min in citrate (1 mM, pH 6.0) using a standard microwave oven followed by a 1-h block in TNB buffer from Perkin Elmer, Woodbridge, Ontario. If horseradish peroxidase amplification-based detection was needed, endogenous peroxidase activity was blocked by an additional incubation with 3 % hydrogen peroxide for 20 min at room temperature. Primary antibodies were incubated overnight at 4°C in TNB. After three wash steps in Tris/NaCl, secondary antibodies were incubated for 1.5 h at room temperature. For amplification, Tritc or Fitc-based tyramide reagent pack from Perkin Elmer was used according to the manufacturer's instructions. Specimens were mounted with Vectashield (Vector laboratories, Burlingame). Sytox blue was given 1:2,000 into the mounting solution to stain for nuclei or topro dye was given in the last washing step after incubation with secondary antibodies at 1:5,000.
Masson Trichrome stainings were performed as per manufacturer's instructions (Trichomes Accustain (Masson), Sigma-Aldrich). Micrographs were acquired using a Leica DMRE confocal microscope. For cardiomyocyte cell size measurements, only strictly cross-sectional cells were analyzed in micrographs taken at the anterior, posterior, septal and lateral wall at mid-ventricular position. At least ten cells were analyzed at each location per field in every heart resulting in [40 cells per heart. Observers were blinded to the experimental group when scanning the slides as well as analyzing the data.
Antibodies
A complete list of applied antibodies is provided in the supplemental files.
NFAT translocation assay
NRCMs were transduced with adenovirus harboring eGFP-NFAT in low serum medium overnight. The next day cells were referred with fresh medium and after another 24 h cells were fixed with 4 % paraformaldehyde and stained with antibodies to detect desmin and nuclear dyes. Total number of GFP ? cells and number of GFP ? nuclei were counted in a blinded fashion. Percentage of bright GFP ? nuclei relative to all GFP ? cells was calculated. For in vivo analysis, 12-week-old mice underwent intubation anesthesia as described above, and at six positions along the long axis of the left ventricle, 5 lL of NFAT-GFP adenovirus with a concentration of 10 9 pfu was injected per animal. Two days following viral delivery, animals underwent TAC or sham surgery as described earlier. Another 2 days later, hearts were harvested for retroperfusion. Percentage of bright GFP ? nuclei relative to all GFP ? cardiomyocytes was calculated.
Sample preparation, immunoblotting, qRT-PCR
Whole heart and isolated cell lysates were prepared as described [25] . Immunoblotting was performed using standard procedures. Protein samples were loaded onto a 4-12 % NuPAGE Novex Bis-Tris Gel (Invitrogen) for electrophoresis. Separated proteins were then transferred onto a polyvinylidene fluoride (PVDF) membrane, blocked with 7 % skim milk in Tris-Buffered Saline Tween-20 (TBST) for 1 h at room temperature, and exposed to primary antibodies over night. Alkaline phosphatase (AP), horseradish peroxidase (HRP), Fitc-or Cy5-conjugated IgGs (Jackson ImmunoResearch, West Grove, PA) were used as secondary antibodies. Fluorescence signal was detected and quantified using a Typhoon 9400 fluorescence scanner together with ImageQuant 5.0 software (Amersham Biosciences). mRNA was enriched using the Quick RNA Mini Prep kit from Zymo Research according to the manufacturer's instructions. cDNA was transcribed using the cDNA preparation kit from Biorad. For RT-PCR, Sybr green (Biorad) was used following the manufacturer's protocol. Data were analyzed with the DDC(t) method. A complete list of the used primers is provided in the supplemental files.
Statistics
Statistical analysis was performed using GraphPad Prism 5.0 (Graphpad Software Inc; www.graphpad.com). p values \ 0.05 were considered significant. To compare two groups with normal distribution, Student's t test was applied, otherwise a non-parametric test was used. For comparison of more than two groups, one-way ANOVA was applied; for the echocardiographic time course analysis, two-way ANOVA was used, both cases inclusive of Bonferroni post hoc tests.
Results
Loss of Fn does not interfere with physiological growth due to voluntary exercise
Germ line deletion of Fn is embryonic lethal with cardiovascular malformation, so studies in adult mice involving Fn deletion required establishment of a conditional global Fn knock out strain [16] . Mice possessing heterozygous expression of Cre-ERT under a CMV-enhanced b-actin promoter were crossed with mice carrying floxed Fn gene leading to loss of Fn expression after tamoxifen (Tx)-induced recombination (knockout animals, KO). A globally expressed promoter was chosen to eliminate Fn rather than a cardiomyocyte-specific deletion since Fn is secreted by heterogeneous cell types within the heart and unlikely to be efficiently removed by excision from only myocytes within the myocardium. After mice had completed physiological cardiac growth at 8 weeks of age, Tx was injected for 10 days in KO and controls. One month later at 12 weeks of age, both control and Tx-treated groups were subjected to voluntary wheel running. The intervening 4-week window allowed recombination and consecutive loss of Fn as well as recovery from transient cardio-depression due to Cre activation by Tx in the heart (suppl. Fig. 1a-b) [2, 15] . Heart weight to body weight ratio (HW/BW) increased similarly about 20 % 4 weeks after training in control and KO animals (Fig. 1a) . Cardiac function was stable and indistinguishable between both groups assessed by echocardiography (Fig. 1b) . Successful Fn knock out ( and lack of ANP induction upon exercise were confirmed with RT-PCR (Fig. 1d ) also without any difference between the groups. Recently, down-regulation of c/EBPb has been identified as central signal in physiological hypertrophy [4] . c/EBPb expression decreased similarly after exercise by 48 % in controls and 46 % in KO mice, respectively (Fig. 1e) . Also, the c/EBPb-dependent gene program was not significantly different between the two groups after training as expression of CITED4, aMHC, Mef2c, Nkx2.5, PGC1a and VEGFa were comparable (Fig. 1f) . Knockdown efficiency for other organs is provided in suppl. Fig. 1d . In summary, loss of Fn has no impact on physiological hypertrophy with regard to cardiac function and activation of underlying c/EBPb-dependent transcriptional program due to voluntary wheel running.
Loss of Fn attenuates ventricular hypertrophy upon pressure overload and delays development of heart failure Pathological hypertrophy was induced by transaortic constriction (TAC) in parallel experiments using the same time course for Tx-treatment and recovery (suppl. Fig. 1b) as described for exercise-induced hypertrophic studies (Fig. 1) . Left ventricular (LV) mass estimated by echocardiography increased by 78 % starting as early as 1-week after TAC (Fig. 2a) in controls. Increase in LV anterior wall thickness in diastole (LVAWd) was detectable at 1-week post-TAC and reached a plateau for the remaining 7 weeks (44 % increase) (Fig. 2b) . Cardiac ejection fraction (EF) was stable for the first 2 weeks post-surgery and heart failure became overt at 3 weeks in parallel with a continuous dilatation of the left ventricle measured as LV internal diameter in diastole (LVIDd, Fig. 2c-d) in the control group. EF decreased to 30 % and LVIDd reached 4.98 mm in control mice at the end of the observation period. Hypertrophic response was attenuated in KO mice as the estimated LV mass increased later than in controls and was significantly reduced at any given time point reaching 57 % increase at the end of the observation (Fig. 2a) . Also LVAWd increase was attenuated in KO mice (33 % increase) (Fig. 2b) . Most importantly, cardiac function was preserved during the entire 8-week-study, however, left ventricular dilatation began at 6 weeks post-TAC, reaching 4.7 mm at the 8 week time point (Fig. 2c,  d ). Heart rate during echocardiographic analysis was similar between groups (suppl. Fig. 1c) . HW/BW ratio was increased in the controls after 8 weeks of TAC by 56 % and significantly lower in KO animals (41 % gain) (Fig. 2e) , supporting the echocardiographic findings. Finally, a clear survival benefit in the Kaplan-Meyer mortality analysis was observed for KO animals (Fig. 2f) as 5 out of 19 control animals died after TAC and all 15 KO mice survived the follow-up period. None of the shamtreated animals died in either group. Taken together, loss of Fn attenuates cardiac hypertrophy upon TAC, delaying development of heart failure and ultimately improving short-term survival.
Loss of Fn blunts cardiomyocyte hypertrophy and NFAT activation upon pressure overload NFAT activation is a major contributor for pathological hypertrophy in response to pathological TAC challenge. Therefore, whole heart lysates 2 days after sham or TAC procedure were prepared from control and KO animals to assess NFAT-related signaling in response to TAC. Under sham condition, Fn expression was significantly reduced in KO mice by 79 %, confirming efficient down-regulation of Fn in our mouse model. Fn expression was significantly induced after TAC in control animals by 268 %, which was markedly reduced in the KO animals after TAC by 46 % compared to sham controls (Fig. 3a) . Strikingly, RCAN1.4 induction by 100 % in controls after TAC was obviated in the KO animals, which showed only 20 % induction upon pressure overload (Fig. 3b) . Consistent with functional data, expression levels of natriuretic peptides and the prohypertrophic fetal gene program were significantly blunted in the KO animals (Fig. 3c, d ). Analysis of cross-sectional area of left ventricular cardiomyocytes confirmed attenuated hypertrophic response in KO mice after TAC compared to controls at the single cell level (Fig. 3e, f) . In controls, cross-sectional area increased from 147 to 302 mm 2 , whereas KO animals showed 118 mm 2 under sham condition, increasing to 199 mm 2 only after TAC. Representative mid-ventricular sections after Masson-Trichrome staining are depicted in Fig. 3g for control and KO mice after sham and TAC procedure. TAC procedure induced increase in number of TUNEL positive cells; however, no significant difference was seen between control and KO animals (Fig. 3h) . In contrast, analysis of fibrosis using RT-PCR for collagen 3a1 (Col3a1) and 1a1 (Col1a1) expression revealed reduction of both isoforms in the KO animals upon TAC procedure compared to control (Fig. 3i, j) . Furthermore, representative immunohistochemistry specimen and immunoblots depicting Fn expression on protein level are provided in suppl. (Fig. 4a) . Upon dephosphorylation, NFAT translocates into the nucleus, so tagging NFAT with GFP allows direct subcellular visualization of NFAT nuclear translocation. NRCMs were infected with adenovirus encoding NFAT-GFP fusion protein (AdNFAT-GFP) [21] . Percentages of clearly fluorescent NFAT ? nuclei relative to all infected GFP ? cardiomyocytes were determined in a blinded fashion. f Quantitative analysis of the cross-sectional area under the conditions as depicted in e. g Masson-Trichrome stainings of mid-ventricular sections in the short axis for the same conditions as depicted in e and f. h TUNEL analysis for apoptotic cells is depicted. Expression of collagen isoforms 1a1 (i) and 3a1 (j) was quantified using RT-PCR. *p \ 0.05; **p \ 0.01; ***p \ 0.001 compared to control. ##p \ 0.01; ###p \ 0.001 compared to sham (Fig. 4c) . NFAT-dependent transcriptional activation was analyzed by RT-PCR to assess functional relevance of NFAT translocation. Fn induced significant up-regulation of RCAN1.4, natriuretic peptides (ANP and BNP) as well as fetal genes (aSA, bMHC) (Fig. 4b) . The significance of Fn for nuclear translocation of NFAT in vivo was assessed in mice, which had received intra-myocardial injection of AdNFAT-GFP 2 days before TAC surgery. At day two d Mice received AdNFAT-GFP via intra-myocardial injection 2 days before surgery. Hearts were harvested 2 days after TAC. Control mouse (left) and KO animal (right) after TAC are depicted (scale: 40 lm). Quantification thereof as described in c. *p \ 0.05; **p \ 0.01; ***p \ 0.001 compared to control after TAC, GFP ? cardiomyocyte nuclei were counted relative to all GFP ? cardiomyocytes similar to the in vitro protocol. KO hearts showed significantly reduced GFP ? nuclei compared to controls ( Fig. 4d; suppl. Figure 3 showing low magnification images for Fig. 4 c, d ). To test whether NFAT activation involves calcineurin, NRCMs were treated with cyclosporine A (CsA) and the pathological gene program was analyzed upon Fn stimulation. As depicted in suppl. Figure 3c , CsA attenuated the induction of the fetal genes. Collectively, these results support the postulate that Fn activates NFAT via calcineurin leading to cardiomyocyte hypertrophy in vitro and in vivo.
Fn attenuates activation of physiologic growth reprogramming in vitro
Fn gene expression was unaltered in healthy adult hearts before and after exercise (Fig. 1c) , but Fn is sufficient for induction of pathological growth in vitro (Figs. 3, 4) . Therefore, the impact of Fn upon physiological hypertrophy signaling was assessed by mimicking induction of physiological growth in vitro by insulin stimulation in the presence of gelatin or Fn. Insulin stimulation reduced c/EBPb expression in cardiomyocytes plated on gelatin (Fig. 5a ), but cells plated on Fn were insensitive for insulin-induced c/EBPb reduction. Induction of c/EBPbdependent transcriptional reprogramming was attenuated in Fn-treated cardiomyocytes as expression of CITED4, aMHC, MEF2c and PGC1a were significantly reduced after insulin treatment compared to gelatin-plated cells (Fig. 5b) . Induction of physiological growth is beneficial, so experiments were performed to determine if insulin treatment would attenuate Fn-induced hypertrophic reprogramming in cultured cells. Interestingly, Fn-induced activation of natriuretic peptides (ANP, BNP) and the fetal genes (bMHC) was not blunted by concurrent insulin stimulation (Fig. 5c) . These same hypertrophy-associated genes were markedly reduced by insulin stimulation when cells were plated on gelatin (Fig. 5d) . In summary, Fn promotes pathological hypertrophic reprogramming in vitro and in vivo and the presence of Fn attenuates activation of the physiological growth program in vitro.
Discussion
Cellular hypertrophy is an essential growth response of post-mitotic myocytes challenged by increased contractile demand to improve hemodynamic output and decrease wall stress. The overall balance of multiple concurrent and sequential stimuli dictates whether the heart as an organ rises to challenge with physiological beneficial growth leading to increased cardiac output or pathological remodeling ultimately leading to HF and increased mortality. Molecular signaling literature is rife with examples of proteins that exacerbate or mitigate myocardial responses to hypertrophic challenge [11, 40] , [20] , [34] .
Results presented here establish Fn up-regulation after TAC challenge as a contributory factor in pathological cardiomyocyte hypertrophy in vivo. Adult-onset conditional genetic deletion of Fn delays myocardial hypertrophic remodeling upon pressure overload and thereby improves short-term survival. The hypertrophic reprogramming induced by Fn appears to be mediated through NFAT signaling in vivo and in vitro. In contrast, physiological growth, known to be NFAT-independent, is unaffected by Fn deletion as evidenced by induction of the established c/EBPb-mediated transcriptional program and functional outcome comparable to wild-type mice. Lack of Fn expression is permissive for physiological growth in cultured cardiomyocytes, whereas presence of Fn attenuates activation of the physiological transcriptional program. Therefore, Fn mediates cardiac hypertrophy allowing physiological growth when absent or contributing to pathological growth upon induction. Changes in the ECM and matricellular proteins after pressure overload are well described in literature [10, 38] . Also induction of Fn in the heart upon pressure overload is well documented leading to speculation about promotion of myocyte growth by Fn in vivo [36] and in vitro. Similarly, Fn expression correlates with remodeling secondary to the underlying pathology of the stressed heart such as TAC [36] , volume overload [31] , myocardial infarction [1] , hypertension [7, 36] , rejection after transplantation [3] or myocarditis [17] . Furthermore, typical growth inducing factors as isoproterenol or angiotensin II do induce Fn expression, which might contribute to the pro-hypertrophic response of cardiomyocytes [42] , [26] . Up to this point, the determination of Fn functional role has not been assessed by genetic deletion in vivo, but results presented here show that Fn contributes to myocyte growth upon pressure overload and, therefore, represents a potential target for therapeutic interference. Fn expression decreases during postnatal development and shows only low level expression in adult organs; therefore, side effects of a putative therapeutic intervention are expected to be minimal in other healthy organs as supported by our finding that loss of Fn under basal conditions, as well as during physiological growth induced by exercise, had no impact on cardiac function. However, Fn is re-expressed upon most types of injury in many organs; therefore, under these conditions, systemic therapeutic inhibition of Fn signaling might be critical and the consequences of interference with induction would need to be assessed in tissue-specific fashion.
A necessary methodological limitation in our study is the global knock out model, which was essential since Fn is synthesized in many different cell types upon injury such as smooth muscle cells, endothelial cells, cardiomyocytes or fibroblasts. As such, we cannot exclude potential systemic, indirect, non-cardiac effects upon hypertrophy, but in vitro experiments reducing the variables to a minimum recapitulate the direct effects of Fn upon cardiomyocyte biology irrespective of the cellular source of Fn in vivo and potential systemic effects. In general, Fn shows low expression in healthy adult tissue and reactivates specifically in damaged organs upon local injury. Four weeks after Tx-treatment to induce Fn gene excision, no cardiac phenotype in echocardiographic assessments or other noncardiac macroscopic abnormalities were evident. Use of AdNFAT-GFP as well as analysis of cross-sectional area of myocytes in vitro and in vivo provides clear evidence of Fn upon NFAT-mediated cardiomyocyte hypertrophy (Figs. 3,  4) . In addition to direct effects of Fn upon cardiomyocytes, Fn as also impacts non-cardiac cell types during cardiac remodeling such as smooth muscle cells or fibroblasts. Potential additional effects of Fn loss upon other cell types within the heart will be the subject of future studies.
Pre-treatment of NRCMs with the calcineurin inhibitor CyclosporinA completely blocked Fn-induced activation of the fetal gene program; therefore, we think calcineurin is involved in the activation of NFAT upon Fn stimulation. In general, calcineurin is activated upon calcium-induced calmodulin activation, and there are three potential pathways possible for calcium release: (1) Fn might activate membrane-bound calcium channels, which release calcium stored in the sarcoplasmatic reticulum [37] , (2) Fn has been shown to co-signal together with Wnt [24] . The noncanonical Wnt/calcium pathway also activates calmodulin upstream of calcineurin, or (3) syndecan-mediated calcineurin activation as proposed recently [9] . This pathway is of particular interest since it has been shown that Fn cosignals with Wnt via syndecan, which would integrate two of these pathways into one signal [24] . Furthermore, knockout of syndecan attenuates pressure overload-induced hypertrophy [9] . These proposed signaling events upstream of calcineurin are speculations and require further study.
As shown in our recent publication [16] , loss of Fn led to further deterioration of cardiac function in a mouse model of myocardial infarction due to impaired wound healing and reduced progenitor cell recruitment. In the present study, loss of Fn was beneficial for the stressed heart upon pressure overload. Besides the quality of the applied stress, induction of Fn expression upon myocardial infarction was a very quick, high increase returning to almost the levels before injury within 4 weeks. In contrast, upon pressure overload Fn continuously raised over time at a lower level of expression. Therefore, we speculate that the duration and intensity might impact the ultimate outcome of Fn stimulation. After loss of Fn, hearts are still capable to respond with physiological hypertrophy and are protected from pathological remodeling upon pressure overload. Therefore, Fn KO hearts seem to represent an advantageous phenotype regarding hypertrophy. However, in case of ischemic injury, loss of Fn is disadvantageous correlating with further reduction of function and impairment of repair. Also in the context of atherosclerosis, blockade of Fn might be disadvantageous because formation of the protective fibrotic cap on the plaque is attenuated and, therefore, prone for rupture potentially leading to myocardial infarction [33] .
In summary, Fn contributes to the acceleration of pathological hypertrophy and concomitant failure of the heart after pressure overload. Findings presented in this study link Fn signaling to NFAT activation. Taken in the context of pro-regenerative beneficial signals mediated by Fn for stem cells [16] , maladaptive effects of Fn in the case of cardiomyocytes highlight the need for further research to tailor induction or inhibition of Fn signals to maximize therapeutic benefit while avoiding loss of beneficial signaling upon selected cell types.
